Histone deacetylase (HDAC) inhibitors: Current evidence for therapeutic activities in pancreatic cancer

Anticancer Research

Volumn 35, Issue 6, 2015, Pages 3129-3135

  Damaskos, Christos ^a   Karatzas, Theodore ^a   Nikolidakis, Lampros ^b   Kostakis, Ioannis D ^a   Karamaroudis, Stefanos ^c   Boutsikos, Georgios ^d   Damaskou, Zoi ^b   Kostakis, Alkiviadis ^e   Kouraklis, Gregory ^a  

^a UNIVERSITY OF ATHENS   (Greece)

^b TYPET Ygeias Melathron Hospital   (Greece)

^c UNIVERSITY OF ATHENS MEDICAL SCHOOL   (Greece)

^d Naval and Veterans Hospital ^*  (Greece)

^e BIOMEDICAL RESEARCH FOUNDATION   (Greece)

Author keywords

Acetylasation; Epigenetics; HDAC; Histone; Inhibitors; Pancreatic cancer; Review

Indexed keywords

ALIPHATIC CARBOXYLIC ACID; BENZAMIDE; HISTONE; HISTONE DEACETYLASE; HISTONE DEACETYLASE INHIBITOR; HYDROXAMIC ACID; NONHISTONE PROTEIN; ROMIDEPSIN; TETRAPEPTIDE; VORINOSTAT; BENZAMIDE DERIVATIVE; FATTY ACID;

ACETYLATION; CANCER CHEMOTHERAPY; CANCER MORTALITY; CANCER PROGNOSIS; CANCER RADIOTHERAPY; CANCER SURGERY; CARCINOGENESIS; CAUSE OF DEATH; DRUG MECHANISM; EPIGENETICS; HUMAN; MONOTHERAPY; PANCREAS CANCER; PLEIOTROPY; PRIORITY JOURNAL; PROTEIN LOCALIZATION; PROTEIN STRUCTURE; PROTEIN TARGETING; REVIEW; CLASSIFICATION; DRUG EFFECTS; GENETIC EPIGENESIS; PANCREATIC NEOPLASMS; PATHOLOGY;

BENZAMIDES; CARCINOGENESIS; EPIGENESIS, GENETIC; FATTY ACIDS; HISTONE DEACETYLASE INHIBITORS; HISTONE DEACETYLASES; HUMANS; HYDROXAMIC ACIDS; PANCREATIC NEOPLASMS;

EID: 84931357766     PISSN: 02507005     EISSN: 17917530     Source Type: Journal    
DOI: None     Document Type: Review

References (62)

1. Ausio J and van Holde KE: Histone hyperacetylation: its effects on nucleosome conformation and stability. Biochemistry 25: 1421-1428, 1986.
2. Hebbes TR, Thorne AW and Crane-Robinson C: A direct link between core histone acetylation and transcriptionally active chromatin. EMBO 7: 1395-1402, 1988.
3. Lee DY, Hayes JJ, Pruss D and Wolffe A: A positive role for histone acetylation in transcription factor access to nucleosomal DNA. Cell 72: 73-84, 1993.
4. Burris HA 3rd, Moore MJ, Andersen J, Green MR, Rothenberg ML, Modiano MR, Cripps MC, Portenoy RK, Storniolo AM, Tarassoff P, Nelson R, Dorr FA, Stephens CD and Von Hoff DD: Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial. J Clin Oncol 1997 15: 2403-2413, 1997.
5. Glozak MA and Seto E: Histone deacetylases and cancer. Oncogene 26: 5420-5432, 2007.
6. Körner M and Tibes U: Histone deacetylase inhibitors: a novel class of anti-cancer agents on its way to the market. Prog Med Chem 46: 205-280, 2008.
7. Kothapalli N, Sarath G and Zempleni J: Biotinylation of K12 in histone H4 decreases in response to DNA double-strand breaks in human JAr choriocarcinoma cells. J Nutr 135: 2337-2342, 2005.
8. Li Z and Zhu WG: Targeting histone deacetylases for cancer therapy: from molecular mechanisms to clinical implications. Int J Biol Sci 10: 757-770, 2014.
9. Kouraklis G and Theocharis S: Histone deacetylase inhibitors: a novel target of anticancer therapy (review). Oncol Rep 15: 489-494, 2006.
10. Bolden JE, Peart MJ and Johnstone RW: Anticancer activities of histone deacetylase inhibitors. Nat Rev Drug Discov 5: 769-784, 2006.
11. Ellis L and Pili R: Histone deacetylase inhibitors: Advancing therapeutic strategies in hematological and solid malignancies. Pharmaceuticals (Basel) 3: 2441-2469, 2010.
12. de Ruijter AJ, van Gennip AH, Caron HN, Kemp S and van Kuilenburg AB: Histone deacetylases (HDACs): characterization of the classical HDAC family. Biochem J 370: 737-749, 2003.
13. Richon VM and O'Brien JP: Histone deacetylase inhibitors: a new class of potential therapeutic agents for cancer treatment. Clin Cancer Res 8: 718-728, 2002.
14. Ouaïssi M, Giger U, Sielezneff I, Pirrò N, Sastre B and Ouaissi A: Rationale for possible targeting of histone deacetylase signaling in cancer diseases with a special reference to pancreatic cancer. J Biomed Biotechnol 2011: 315939, 2011.
15. Peulen O, Gonzalez A, Peixoto P, Turtoi A, Mottet D, Delvenne P and Castronovo V: The anti-tumor effect of HDAC inhibition in a human pancreas cancer model is significantly improved by the simultaneous inhibition of cyclooxygenase 2. PLoS One 8: e75102, 2013.
16. Koutsounas I, Giaginis C, Patsouris E and Theocharis S: Current evidence for histone deacetylase inhibitors in pancreatic cancer. World J Gastroenterol 19: 813-828, 2013.
17. Marks PA: The clinical development of histone deacetylase inhibitors as targeted anticancer drugs. Expert Opin Investig Drugs 19: 1049-1066, 2010.
18. Prince HM, Bishton MJ and Harrison SJ: Clinical studies of histone deacetylase inhibitors. Clin Cancer Res 15: 3958-3969, 2009.
19. Marsoni S, Damia G and Camboni G: A work in progress: the clinical development of histone deacetylase inhibitors. Epigenetics 3: 164-171, 2008.
20. Bi G and Jiang G: The molecular mechanism of HDAC inhibitors in anticancer effects. Cell Mol Immunol 3: 285-290, 2006.
21. Ellis L, Hammers H and Pili R: Targeting tumor angiogenesis with histone deacetylase inhibitors. Cancer Lett 280: 145-153, 2009.
22. Ma WW and Adjei AA: Novel agents on the horizon for cancer therapy. CA Cancer J Clin 59: 111-137, 2009.
23. Walkinshaw DR and Yang XJ: Histone deacetylase inhibitors as novel anticancer therapeutics. Curr Oncol 15: 237-243, 2008.
24. Koutsounas I, Giaginis C and Theocharis S: Histone deacetylase inhibitors and pancreatic cancer: Are there any promising clinical trials? World J Gastroenterol 19: 1173-1181, 2013.
25. Kelly WK and Marks PA: Drug insight: Histone deacetylase inhibitors-development of the new targeted anticancer agent suberoylanilide hydroxamic acid. Nat Clin Pract Oncol 2: 150-157, 2005.
26. Kelly WK, Richon VM, O'Connor O, Curley T, MacGregor-Curtelli B, Tong W, Klang M, Schwartz L, Richardson S, Rosa E, Drobnjak M, Cordon-Cordo C, Chiao JH, Rifkind R, Marks PA and Scher H: Phase I clinical trial of histone deacetylase inhibitor: suberoylanilide hydroxamic acid administered intravenously. Clin Cancer Res 9: 3578-3588, 2003.
27. Angst E, Dawson DW, Nguyen A, Park J, Go VL, Reber HA, Hines OJ and Eibl G: Epigenetic regulation affects N-myc downstream-regulated gene 1 expression indirectly in pancreatic cancer cells. Pancreas 39: 675-679, 2010.
28. Schüler S, Fritsche P, Diersch S, Arlt A, Schmid RM, Saur D and Schneider G: HDAC2 attenuates TRAIL-induced apoptosis of pancreatic cancer cells. Mol Cancer 9: 80, 2010.
29. García-Morales P, Gómez-Martínez A, Carrato A, Martínez-Lacaci I, Barberá VM, Soto JL, Carrasco-García E, Menéndez-Gutierrez MP, Castro-Galache MD, Ferragut JA and Saceda M: Histone deacetylase inhibitors induced caspase-independent apoptosis in human pancreatic adenocarcinoma cell lines. Mol Cancer Ther 4: 1222-1230, 2005.
30. Donadelli M, Costanzo C, Beghelli S, Scupoli MT, Dandrea M, Bonora A, Piacentini P, Budillon A, Caraglia M, Scarpa A and Palmieri M: Synergistic inhibition of pancreatic adenocarcinoma cell growth by trichostatin A and gemcitabine. Biochim Biophys Acta 1773: 1095-1106, 2007.
31. Bai J, Demirjian A, Sui J, Marasco W and Callery MP: Histone deacetylase inhibitor trichostatin A and proteasome inhibitor PS-341 synergistically induce apoptosis in pancreatic cancer cells. Biochem Biophys Res Commun 348: 1245-1253, 2006.
32. Chien W, Lee DH, Zheng Y, Wuensche P, Alvarez R, Wen DL, Aribi AM, Thean SM, Doan NB, Said JW and Koeffler HP: Growth inhibition of pancreatic cancer cells by histone deacetylase inhibitor belinostat through suppression of multiple pathways including HIF, NFkB, and mTOR signaling in vitro and in vivo. Mol Carcinog 53: 722-735, 2014.
33. Grassadonia A, Cioffi P, Simiele F, Iezzi L, Zilli M and Natoli C: Role of Hydroxamate-Based Histone Deacetylase Inhibitors (Hb-HDACIs) in the Treatment of Solid Malignancies. Cancers (Basel) 5: 919-942, 2013.
34. Ouaïssi M, Silvy F, Loncle C, Ferraz da Silva D, Martins Abreu C, Martinez E, Berthézene P, Cadra S, Le Treut YP, Hardwigsen J, Sastre B, Sielezneff I, Benkoel L, Delgrande J, Ouaissi A, Iovanna J, Lombardo D and Mas E: Further characterization of HDAC and SIRT gene expression patterns in pancreatic cancer and their relation to disease outcome. PLoS One 9: e108520, 2014.
35. Feng W, Zhang B, Cai D and Zou X: Therapeutic potential of histone deacetylase inhibitors in pancreatic cancer. Cancer Lett 347: 183-190, 2014.
36. Li J, Bonifati S, Hristov G, Marttila T, Valmary-Degano S, Stanzel S, Schnölzer M, Mougin C, Aprahamian M, Grekova SP, Raykov Z, Rommelaere J and Marchini A: Synergistic combination of valproic acid and oncolytic parvovirus H-1PV as a potential therapy against cervical and pancreatic carcinomas. EMBO Mol Med 5: 1537-1555, 2013.
37. Tinari N, De Tursi M, Grassadonia A, Zilli M, Stuppia L, Iacobelli S and Natoli C: An epigenetic approach to pancreatic cancer treatment: the prospective role of histone deacetylase inhibitors. Curr Cancer Drug Targets 12: 439-452, 2012.
38. Iwahashi S, Ishibashi H, Utsunomiya T, Morine Y, Ochir TL, Hanaoka J, Mori H, Ikemoto T, Imura S and Shimada M: Effect of histone deacetylase inhibitor in combination with 5-fluorouracil on pancreas cancer and cholangiocarcinoma cell lines. J Med Invest 58: 106-109, 2011.
39. Paller CJ, Wissing MD, Mendonca J, Sharma A, Kim E, Kim HS, Kortenhorst MS, Gerber S, Rosen M, Shaikh F, Zahurak ML, Rudek MA, Hammers H, Rudin CM, Carducci MA and Kachhap SK: Combining the pan-aurora kinase inhibitor AMG 900 with histone deacetylase inhibitors enhances antitumor activity in prostate cancer. Cancer Med 3: 1322-1335, 2014.
40. Lakshmaiah KC, Jacob LA, Aparna S, Lokanatha D and Saldanha SC: Epigenetic therapy of cancer with histone deacetylase inhibitors. J Cancer Res Ther 10: 469-478, 2014.
41. Wang G, He J, Zhao J, Yun W, Xie C, Taub JW, Azmi A, Mohammad RM, Dong Y, Kong W, Guo Y and Ge Y: Class I and class II histone deacetylases are potential therapeutic targets for treating pancreatic cancer. PLoS One 7: e52095, 2012.
42. Donadelli M, Costanzo C, Faggioli L, Scupoli MT, Moore PS, Bassi C, Scarpa A and Palmieri M: Trichostatin A, an inhibitor of histone deacetylases, strongly suppresses growth of pancreatic adenocarcinoma cells. Mol Carcinog 38: 59-69, 2003.
43. Ryu JK, Lee WJ, Lee KH, Hwang JH, Kim YT, Yoon YB and Kim CY: SK-7041, a new histone deacetylase inhibitor, induces G2-M cell cycle arrest and apoptosis in pancreatic cancer cell lines. Cancer Lett 237: 143-154, 2006.
44. Schneider G, Reichert M, Saur D, Hamacher R, Fritsch R and Schmid RM: HDAC3 is linked to cell cycle machinery in MiaPaCa2 cells by regulating transcription of skp2. Cell Prolif 40: 522-531, 2007.
45. Moore PS, Barbi S, Donadelli M, Costanzo C, Bassi C, Palmieri M and Scarpa A: Gene expression profiling after treatment with the histone deacetylase inhibitor trichostatin A reveals altered expression of both pro- and anti-apoptotic genes in pancreatic adenocarcinoma cells. Biochim Biophys Acta 1693: 167-176, 2004.
46. von Burstin J, Eser S, Paul MC, Seidler B, Brandl M, Messer M, von Werder A, Schmidt A, Mages J, Pagel P, Schnieke A, Schmid RM, Schneider G and Saur D: E-cadherin regulates metastasis of pancreatic cancer in vivo and is suppressed by a SNAIL/HDAC1/HDAC2 repressor complex. Gastroenterology 137: 361-371, 2009.
47. Gahr S, Ocker M, Ganslmayer M, Zopf S, Okamoto K, Hartl A, Leitner S, Hahn EG and Herold C: The combination of the histone-deacetylase inhibitor trichostatin A and gemcitabine induces inhibition of proliferation and increased apoptosis in pancreatic carcinoma cells. Int J Oncol 31: 567-576, 2007.
48. Piacentini P, Donadelli M, Costanzo C, Moore PS, Palmieri M and Scarpa A: Trichostatin A enhances the response of chemotherapeutic agents in inhibiting pancreatic cancer cell proliferation. Virchows Arch 448: 797-804, 2006.
49. Haefner M, Bluethner T, Niederhagen M, Moebius C, Wittekind C, Mossner J, Caca K and Wiedmann M: Experimental treatment of pancreatic cancer with two novel histone deacetylase inhibitors. World J Gastroenterol 14: 3681-3692, 2008.
50. Venkannagari S, Fiskus W, Peth K, Atadja P, Hidalgo M, Maitra A and Bhalla KN: Superior efficacy of co-treatment with dual PI3K/mTOR inhibitor NVP-BEZ235 and pan-histone deacetylase inhibitor against human pancreatic cancer. Oncotarget 3: 1416-1427, 2012.
51. Mehdi O, Françoise S, Sofia CL, Urs G, Kevin Z, Bernard S, Igor S, Anabela CD, Dominique L, Eric M and Ali O: HDAC gene expression in pancreatic tumor cell lines following treatment with the HDAC inhibitors panobinostat (LBH589) and trichostatine (TSA). Pancreatology 12: 146-155, 2012.
52. Wang G, Niu X, Zhang W, Caldwell JT, Edwards H, Chen W, Taub JW, Zhao L and Ge Y: Synergistic antitumor interactions between MK-1775 and panobinostat in preclinical models of pancreatic cancer. Cancer Lett 356: 656-668, 2015.
53. Kumagai T, Wakimoto N, Yin D, Gery S, Kawamata N, Takai N, Komatsu N, Chumakov A, Imai Y and Koeffler HP: Histone deacetylase inhibitor, suberoylanilide hydroxamic acid (Vorinostat, SAHA) profoundly inhibits the growth of human pancreatic cancer cells. Int J Cancer 121: 656-665, 2007.
54. Nawrocki ST, Carew JS, Pino MS, Highshaw RA, Andtbacka RH, Dunner K Jr, Pal A, Bornmann WG, Chiao PJ, Huang P, Xiong H, Abbruzzese JL and McConkey DJ: Aggresome disruption: a novel strategy to enhance bortezomib-induced apoptosis in pancreatic cancer cells. Cancer Res 66: 3773-3781, 2006.
55. Arnold NB, Arkus N, Gunn J and Korc M: The histone deacetylase inhibitor suberoylanilide hydroxamic acid induces growth inhibition and enhances gemcitabine-induced cell death in pancreatic cancer. Clin Cancer Res 13: 18-26, 2007.
56. Chun SG, Zhou W and Yee NS: Combined targeting of histone deacetylases and hedgehog signaling enhances cytoxicity in pancreatic cancer. Cancer Biol Ther 8: 1328-1339, 2009.
57. Dovzhanskiy DI, Arnold SM, Hackert T, Oehme I, Witt O, Felix K, Giese N and Werner J: Experimental in vivo and in vitro treatment with a new histone deacetylase inhibitor belinostat inhibits the growth of pancreatic cancer. BMC Cancer 12: 226, 2012.
58. Spratlin JL, Pitts TM, Kulikowski GN, Morelli MP, Tentler JJ, Serkova NJ and Eckhardt SG: Synergistic activity of histone deacetylase and proteasome inhibition against pancreatic and hepatocellular cancer cell lines. Anticancer Res 31: 1093-1103, 2011.
59. Natoni F, Diolordi L, Santoni C and Gilardini Montani MS: Sodium butyrate sensitises human pancreatic cancer cells to both the intrinsic and the extrinsic apoptotic pathways. Biochim Biophys Acta 1745: 318-329, 2005.
60. Ammerpohl O, Trauzold A, Schniewind B, Griep U, Pilarsky C, Grutzmann R, Saeger HD, Janssen O, Sipos B, Kloppel G and Kalthoff H: Complementary effects of HDAC inhibitor 4-PB on gap junction communication and cellular export mechanisms support restoration of chemosensitivity of PDAC cells. Br J Cancer 96: 73-81, 2007.
61. Sato N, Ohta T, Kitagawa H, Kayahara M, Ninomiya I, Fushida S, Fujimura T, Nishimura G, Shimizu K and Miwa K: FR901228, a novel histone deacetylase inhibitor, induces cell cycle arrest and subsequent apoptosis in refractory human pancreatic cancer cells. Int J Oncol 24: 679-685, 2004.
62. Fritsche P, Seidler B, Schüler S, Schnieke A, Göttlicher M, Schmid RM, Saur D and Schneider G: HDAC2 mediates therapeutic resistance of pancreatic cancer cells via the BH3-only protein NOXA. Gut 58: 1399-1409, 2009.